



HAL
open science

Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition

Maggie Roy, Cécile Cardoso, Olène Dorieux, Carole Malgorn, Stéphane Epelbaum, Fanny Petit, Audrey Kraska, Emmanuel Brouillet, Benoit Delatour, Martine Perret, et al.

► To cite this version:

Maggie Roy, Cécile Cardoso, Olène Dorieux, Carole Malgorn, Stéphane Epelbaum, et al. Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. *Neurobiology of Aging*, 2015, 36 (1), pp.149-156. 10.1016/j.neurobiolaging.2014.07.017 . mnhn-02291873

HAL Id: mnhn-02291873

<https://mnhn.hal.science/mnhn-02291873>

Submitted on 25 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Age-associated evolution of plasmatic amyloid in mouse lemur primates: Relationship with intracellular amyloid deposition

Maggie Roy^{a,b,c,*}, Cécile Cardoso^{a,b,*}, Olène Dorieux^{a,b,d}, Carole Malgorn^{a,b}, Stephane Epelbaum^e, Fanny Petit^{a,b}, Audrey Kraska^{a,b}, Emmanuel Brouillet^{a,b}, Benoît Delatour^e, Martine Perret^d, Fabienne Aujard^d, and Marc Dhenain^{a,b}

^a CEA, DSV, I2BM, MIRGen, URA CEA CNRS 2210, 18 route du panorama 92 265 Fontenay-aux-Roses cedex, France.

^b CNRS, URA 2210, 18 route du panorama 92 265 Fontenay-aux-Roses cedex, France.

^c Research Center on Aging, Université de Sherbrooke, 1036 Belvedere South, J1H 4C4, Sherbrooke, QC, Canada.

^d CNRS UMR 7179, MNHN, 1 avenue du Petit Château, 91800 Brunoy, France.

^e Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, and Inserm, U 1127, and CNRS UMR 7225, and ICM, 75013, Paris, France.

* These authors contributed equally to the work

Corresponding author:

Marc Dhenain
MIRGen, URA CEA CNRS 2210
18 route du panorama
92 265 Fontenay-aux-Roses cedex
France.
Tel: +33 1 46 54 81 92 ; Fax: +33 1 46 54 84 51 ; Mail: Marc.Dhenain@cea.fr

ABSTRACT

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid- β peptide (A β) deposition in the brain is one of its hallmarks and the measure of plasma A β is considered to be a biomarker for anti-amyloid drug efficacy in animal models of AD. However, age-associated plasmatic A β modulation in animal models is practically never addressed in the literature. Mouse lemur primates are used as a model of normal and AD-like cerebral aging. Here, we studied the effect of age on plasmatic A β in 58 mouse lemurs aged from 1 to 10 years. A subset of animals presented high plasmatic A β and the proportion of animals with high plasmatic A β was higher in aged animals as compared to young ones. Histological evaluation of the brain of some of these animals was carried out to assess extracellular and intracellular amyloid load. In aged lemurs, plasmatic A β was negatively correlated with the density of neurons accumulating deposits of A β .

Key Words: Amyloid; Alzheimer; Intracellular amyloid, Cerebral aging; Lemur; *Microcebus murinus*, Plasma

1. INTRODUCTION

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. It is characterized by two main microscopic lesions: senile plaques and neurofibrillary tangles. Senile plaques are mainly constituted of aggregated extracellular deposition of amyloid- β ($A\beta$) peptides. These latter come from the proteolytic processing of the transmembrane protein APP (amyloid- β precursor protein) into mainly two types of $A\beta$ peptides: $A\beta_{40}$ and $A\beta_{42}$. Neurofibrillary tangles are constituted of intraneuronal accumulation of abnormally phosphorylated tau proteins. The amyloid cascade hypothesis is currently the dominant explanation of AD aetiology. It suggests that a chronic imbalance between production and clearance of $A\beta$ peptides results in intracerebral accumulation of $A\beta$. This leads to a cascade of events that cause AD (Hardy and Selkoe, 2002; Sperling et al., 2011). In addition to senile plaques, $A\beta$ is also present as soluble toxic oligomeric forms (Lacor et al., 2004; Selkoe, 2008) as well as intracellular $A\beta$ deposits (Gouras et al., 2000; Gyure et al., 2001). The latter form occurs before plaque formation (Gyure et al., 2001; Wirths et al., 2001) and is also toxic for the brain (Wirths et al., 2004).

In humans, biomarkers of $A\beta$ are used to facilitate AD diagnosis (Blennow et al., 2010; Jack et al., 2009) and evaluate the efficacy of anti-AD therapies (Relkin et al., 2009). The most widely used biochemical marker of $A\beta$ is the measurement of $A\beta_{42}$ level in cerebrospinal fluid (CSF). Indeed, the concentration of $A\beta_{42}$ in CSF is lower in AD patients than in healthy controls (Andreasen et al., 1999). The decrease in CSF $A\beta_{42}$ in AD has been attributed, at least in part, to deposition of $A\beta$ in plaques in the brain (Motter et al., 1995; Strozyk et al., 2003). Although measures of $A\beta_{42}$ in the CSF are widely used in the clinic, it is interesting to outline that $A\beta_{40}$ is the main $A\beta$ component in the brain and in peripheric fluids and the concentration of $A\beta_{40}$ in the CSF is assumed to reflect the total amount of $A\beta$ proteins in the brain (Wiltfang et al. 2007). Also, recent studies suggested that including measurement of CSF $A\beta_{40}$ levels in a decision tree can help to better discriminate patients with AD in ambiguous clinical diagnosis cases (Slaets et al., 2013; Sauvee et al., 2014).

As plasma sampling is simpler and less invasive than a lumbar puncture, several authors have investigated the ability to use plasmatic A β as an alternative to measurements in CSF. The published data on plasma A β from single cross-sectional studies in humans are however still conflicting: plasma A β of AD patients have been reported to be higher, lower, or unchanged as compared to controls (Buerger et al., 2009; Roher et al., 2009; Sobow et al., 2005). However, a meta-analysis recently suggested higher baseline plasma A β_{40} and A β_{42} in cognitively normal subjects who converted to AD (Song et al., 2011). Then when AD develops, plasmatic A β_{42} declines (Song et al., 2011). Also, direct evaluation of relationships between plasma A β loads and intracerebral amyloid load measures by imaging methods have revealed a positive relationship between plasma A β_{40} levels and cerebral amyloid load and a negative relationship between A β_{42} /A β_{40} ratio and cerebral amyloid load (Devanand et al., 2011). In addition to AD, other factors such as aging have been reported to increase baseline plasma A β in humans (Lopez et al., 2008). In addition to its potential use for AD diagnosis, one possible application of measures of plasmatic A β is the evaluation of target engagements for therapies modulating A β synthesis. For example, treatments with γ -secretase inhibitors are shown to reduce the level of A β_{40} in the plasma (Fleisher et al., 2008).

Animal models are widely used to discover fundamental mechanisms associated to AD pathology and to evaluate new drugs against AD. Transgenic mouse models of amyloidosis expressing mutant forms of human APP and presenilin 1 (PS1) (Duyckaerts et al., 2008) and spontaneous models of brain aging such as primates (Picq et al., 2012) are the most widely used models to study various aspects of AD pathology and therapy. As in humans, A β modulation in animal models can be evaluated in the CSF (Das et al., 2011; Liu and Duff, 2008). In small animals, A β can be measured more easily in the plasma. These measurements are used to evaluate the effects of various biological factors such as APOE genotype on A β clearance (Sharman et al., 2010) or to assess therapeutic effects of potential drugs. For example, studies in transgenic mouse models of AD have shown that treatments with γ - or β -

secretase inhibitors reduce plasmatic A β ₄₂ and A β ₄₀ (Chang et al., 2004; Kounnas et al., 2010; Lanz et al., 2010). Modulation of plasmatic A β can also be used to follow-up the effects of anti-A β immunotherapies in mice (Lemere, 2009; Wang et al., 2011; Yamada et al., 2009). Studies of therapeutic interventions in primates also revealed changes in plasmatic A β . For example, increased plasmatic A β is detected following active immunotherapy in primates such as the mouse lemur (Trouche et al., 2009; Joseph-Mathurin et al., 2013) and the caribbean vervet (Lemere et al., 2004).

Few studies in animal models have focused on the modulation of plasmatic A β during aging. Studies in the Tg2576 transgenic mice, a model that develops A β plaques at 12 months, suggested constant plasma A β until 12 months of age, after what, an age-associated decrease in plasma A β was detected in coincidence with the marked cerebral deposition of A β (Kawarabayashi et al., 2001). Another study in dogs showed higher plasmatic A β in young animals as compared to old cognitively unimpaired animals and higher A β in old animals with mild cognitive impairment as compared to either cognitively unimpaired or severely affected dogs (Gonzalez-Martinez et al., 2011). To the best of our knowledge, age-associated modulation of plasmatic A β has never been addressed in non-human primates. The aim of the current study was thus to evaluate the effect of age on plasmatic A β in the mouse lemur primate (*Microcebus murinus*). This small primate (70-150g) has a short lifespan of approximately 12 years. A subcategory of aged lemurs can develop both extracellular (Bons et al., 1991) and intracellular (Joseph-Mathurin et al., 2013; Mestre-Frances et al., 2000) A β deposits and Tau pathologies (Kraska et al., 2011). Our results suggest increased plasmatic A β levels in a subpopulation of aged lemurs. We also show that a high plasmatic A β in aged animals is associated to a low level of intraneuronal material detected by the 4G8 monoclonal antibody and that corresponds to A β accumulation.

2. MATERIALS AND METHODS

2.1 Animals

Fifty eight mouse lemurs were involved in the current study (n=25 young animals (1-5.5 years) and n=33 aged animals (5.5-10 years)). They were all born in a laboratory breeding colony (Brunoy, France, Agreement n°E91-114-1). All experiments were carried out in accordance with European Communities Council directive (86/609/EEC) under the authorization number 91–326 from the “Direction Départementale des Services Vétérinaires de l’Essonne” and the Internal Review Board of the URA CEA CNRS 2210.

2.2 Blood collection, pre-treatment and plasmatic A β detection

Blood was collected from the saphenous vein. The vein was pricked with a needle at a 45° angle and blood was collected in small heparinised capillaries (60 μ l). Every blood sampling was done at the same time in the morning. All blood samples were kept on ice and centrifuged (2000g; 10 min) at 4°C in the 15 min following the collection. The plasma layer was then collected in 200 μ l polypropylene tubes. A cocktail of proteases inhibitors (Complete Mini; Roche, Meylan, France) was added to each plasma sample at a final concentration of 1X. The samples were then allowed to freeze in a -80°C freezer and were then kept at -80°C until their analysis.

Plasmatic level of A β ₄₀ was assessed with enzyme-linked immunosorbent assay (ELISA) kits “Human β amyloid 1-40” (Invitrogen, Saint Aubin, France). The ELISA were carried out following the manufacturer’s protocol and executed using non-diluted plasma samples.

2.3 Brain tissue processing and immunohistochemical staining

The brains of seven aged mouse lemurs with known concentration of plasmatic A β were removed and fixed in 4% formalin after the natural death of animals. Brains were plunged in a

15% sucrose solution for 24 hours and then in a 30% sucrose solution for cryoprotection. They were then frozen and sliced into 40- μ m-thick coronal sections on a freezing microtome. Slices were then stored at -20°C in a storage solution (glycerol 30%, ethylene glycol 30% and phosphate buffer 0.1M).

Brains sections from all studied animals were first immunostained using the 4G8 antibody directed against the residues 17-24 of A β . The 4G8 antibody is routinely used to detect amyloid deposits (Alafuzoff et al., 2008). Sections were pretreated with hydrogen peroxide (0.3%), then incubated in a phosphate buffered (0.1M) saline (0.9%) and triton (0.2%) solution (PBS+Tx) with normal goat serum (NGS;4.5%). Sections were then incubated for two days into PBS+Tx solution with NGS (3%) and the primary antibody mouse monoclonal 4G8 antibody; 1/500; Covance Signet Antibodies, Debham, MA, USA). Sections were incubated for one hour into a PBS+Tx solution with NGS (3%) and the secondary antibody (biotinylated goat anti-mouse antibody; 1/1000; Vector Laboratories, Burlingame, CA, USA). The signal was amplified using an avidin-biotin complex for one hour (Vectastain, Vector Laboratories). The final reaction used diaminobenzidine (DAB; Vector Laboratories) for two minutes as the chromogen (brown stains). Counterstaining with cresyl violet was used to distinguish cells nuclei. Negative controls were performed by omitting the primary antibody in the procedure. Positive controls were performed using formalin-fixed brain sections of APP/PS1dE9 mice (Garcia-Alloza et al., 2006). All sections were mounted on slides and viewed using a standard microscope (Zeiss Axioplan, Germany).

As 4G8 cross-reacts with APP (Aho et al., 2010), we performed control experiments to assess the specificity of 4G8 immunostaining. We carried out double immunofluorescent staining (n= 5 animals) with a cocktail of primary antibodies: 4G8 (1/5000) and A8717, a polyclonal antibody directed against the amino acids 676-695 of the C-terminus part of the APP (1/500, SigmaAldrich, St Louis, MO, USA). Primary antibodies were incubated overnight at room temperature. Detection-visualization of primary antibodies was performed using a cocktail of secondary antibodies: Goat anti-Mouse Fluor Hylite 555 (1/200, Jackson Immunoresearch, West

Grove, PA, USA) to detect 4G8 and donkey anti-Rabbit antibody conjugated to an Alexa Fluor 488 (1/200; Invitrogen) to detect A8717. Sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI) and treated for 30 sec in a saturated Sudan Black solution to decrease a-specific autofluorescence (Delatour et al., 2001).

2.4 Morphological analysis

Intracellular 4G8 positive deposits, revealed by immunoperoxidase stainings, were detected mainly in the parietal cortex, hippocampus, and in the caudate nucleus (see results). The optical fractionator method was used to quantify the deposit-positive cells in these regions (West et al., 1991). Aggregate-positive cells were counted using a Zeiss Axioplan microscope equipped with a digital color camera, x–y motorized stage controller and Mercator (ExploraNova) stereology software. The regions of interest were delineated using a 1.5x objective, in accordance with a mouse lemur brain atlas (Bons et al., 1998). Sampling was performed bilaterally within the delineated areas with a 20x objective. The analysis was done on slices spaced out of 800 μm . Analysis was performed from squares sampling the structure (14.8% of the surface). The density of cells presenting intracellular aggregates (number of cells per mm^2 of surface sampled) was calculated.

For the purpose of control experiments colocalization of 4G8-positive intracellular objects and A8717-positive objects were assessed in the caudate nucleus. The analysis was performed on 5 animals with ImageJ and the JACOP plugin (Bolte and Cordelieres, 2006) We studied the cytofluorograms and calculated a mean Pearson's and overlap coefficient for all neurons exhibiting both 4G8 and/or A8717 signals.

2.5 Statistical analysis

Spearman's test was used to evaluate the correlation between plasmatic A β and age or cerebral 4G8 positive objects. Chi-square test was used to compare the proportion of animals with low and high plasma A β in young and aged animals. Student's t test was used to perform

group comparisons. Statistical analysis was made using PRISM 5 software (Graphpad, La Jolla, CA, USA). *P* value < 0.05 was set as statistically significant level for each test.

3. RESULTS

3.1 Plasmatic A β

Plasmatic A β was evaluated in 1 to 10 years-old mouse lemurs. No significant correlation was noted between plasmatic A β_{40} and age (Fig. 1A). However, a large heterogeneity was observed in aged animals, as compared to young ones. Indeed, when we separated plasma A β in two categories: low level (≤ 55 pg/ml) and high level (> 55 pg/ml), we found a significantly larger number of aged animals with a high plasma A β as compared to young animals (43 versus 16 % of the old and young animals respectively; $X^2=4.64$; $p=0.031$). The concentrations of plasma A β in the animals classified as low or high plasma A β levels were significantly different (Mean \pm Standard error of the mean (SEM)=36.2 \pm 1.5 pg/ml and 86.7 \pm 7.9 pg/ml, Student's t test, $p<0.0001$, respectively).

3.2 Neuropathology

The brains of seven aged animals (6.1 to 9.3 years old) studied for plasmatic A β could be evaluated by neuropathology (four animals had low plasmatic A β (Fig. 1A, green dots) and three had high plasma A β (Fig. 1A, red dots). Extracellular A β deposits were observed in the cortex of only one out of the seven aged animals analyzed (Fig. 2H). It was an 8 year-old animal with a high concentration of plasmatic A β (59.9 pg/ml). The two other animals with high plasmatic A β (127.5 and 63.5 pg/ml) did not have plaques. In all the animals, 4G8-positive objects were mainly observed in the form of intracellular deposits (Fig. 2C-G). These deposits were present in several brain regions such as the parietal cortex, hippocampus, caudate nucleus and in a ventral

brain areas corresponding to the nucleus basalis of Meynert (Bons et al., 1998). They appeared as an accumulation of spherical vesicles within the cells (Fig. 2A-G, Fig. 3A-B). The density of vesicles varied within the cells: the vesicles density could be low (Fig. 2G, label 1); it could be higher, providing an aspect of diffuse deposition (Fig. 2G, label 2); in some cases, the vesicles were densely packed within the cells (Fig. 2G, label 3). Overall, the densely packed deposits were less numerous than the less packed more diffuse deposits.

The 4G8 positive objects were found in the same brain locations regardless of the immunostaining method (immunoperoxidase or immunofluorescence). No fluorescent staining could be detected in sections incubated without primary antibodies, indicating the absence of confounding autofluorescent background that may interfere with the analysis of double staining. Immunodetection of APP with the A8717 antibody revealed intracellular staining of numerous neurons in almost all brain regions. APP immunostaining was hence not exclusively observed in the neurons displaying 4G8 immunoreactivity (Fig. 3A). In the caudate nucleus 445 cells were randomly selected for APP/4G8 co-labelling analysis. 396 of these neurons (i.e. 89%) were A8717-positive and 4G8-negative (Fig 3A); while only 9 neurons (2%) of the sampled population were A8717-negative and 4G8-positive (Fig 3A). Nine percent (40/445) of the neurons were both A8717-positive and 4G8-positive; however in this subpopulation of double-stained neurons the intracellular topographies of A8717 and 4G8 immunostainings were different and poorly colocalized: low overlap coefficients were indeed observed between 4G8 and A8717 signals ($r=0.569$ CI95% 0.528-0.621) in the five studied animals (Fig. 3C). These results showed that, in our experimental conditions, 4G8 immunostaining does not cross-react with APP and therefore points to local accumulations of A β .

In the three quantified brain regions, the 4G8-positive cells were more numerous in the animals with low plasma amyloid load as compared to animals with high plasma amyloid load (Fig. 1B). Interestingly, the total number of 4G8-positive cells in the caudate nucleus was negatively correlated to plasmatic A β_{40} (Fig. 1C; $r=-0.86$, $p<0.05$).

4. DISCUSSION

Plasma A β is used as a biomarker for drug efficiency studies in animal models of AD (Chang et al., 2004; Kounnas et al., 2010; Lanz et al., 2010). However, age-associated plasmatic A β modulation in animal models is practically never addressed in the literature. Also data on evolution of plasma A β during aging and AD in humans are still controversial (Buerger et al., 2009; Roher et al., 2009; Sobow et al., 2005; Song et al., 2011). Assessing the effect of age and pathology progression on plasmatic A β in primate models is thus a crucial issue. Here, we evaluated plasmatic A β in mouse lemur primates, a model of cerebral aging that can spontaneously develop intracellular (Joseph-Mathurin et al., 2013; Mestre-Frances et al., 2000) and extracellular (Bons et al., 1991) A β deposits while aging. In mouse lemurs, plasma A β is already used as a biomarker in drug studies (Trouche et al., 2009; Joseph-Mathurin et al., 2013) although the age effect on plasmatic A β has never been studied. In mouse lemurs, plasma A β concentrations are much lower than in transgenic mice, as mouse lemurs are non transgenic animals who are not overexpressing A β . Because of the low plasma A β concentration in lemurs, A β_{42} levels are usually below the limit of detection with classical ELISA tests (Trouche et al., 2009). We thus focused on A β_{40} that is the main A β component in the brain. In humans A β_{40} in the CSF is assumed to reflect the total amount of A β proteins in the brain (Wiltfang et al., 2007) and a positive relationship has been reported between plasma A β_{40} levels and cerebral amyloid load measured by imaging methods (Devanand et al., 2011). A β_{40} in the plasma is also used to follow-up the action of drugs modulating A β synthesis or promoting amyloid clearance in animals (Chang et al., 2004; Lanz et al., 2010, Trouche et al., 2009) and humans (Fleisher et al., 2008). Interestingly, as opposed to transgenic mice (data not shown), we found two categories of aged mouse lemurs: low (57%) and high (43%) plasmatic A β (Fig. 1A). This suggests that in lemurs, A β is modulated differently amongst animals with aging.

Only one animal out of the seven lemurs evaluated by histology, displayed extracellular A β plaques. This animal had high plasma A β . However, the other animals with higher plasmatic A β did not show any extracellular A β deposits. Extracellular deposits were not found in mouse lemurs with low plasma A β . This possibly suggests a lack of correlation between these two parameters. However, as the number of extracellular deposits is very rare in mouse lemurs, the number of animals included in our histological evaluation is likely too low to establish such a correlation.

Strikingly intracellular accumulation of 4G8 positive material was detected in all studied animals (with density of intraneuronal staining varying from one case to the other). We selected the 4G8 antibody to immunodetect intraneuronal deposits as it is a standard antibody used in animal and human tissues to reveal A β deposition. 4G8 immunohistochemistry is even considered as a reference method for multicentric studies (Alafuzoff et al., 2008) and for the standardization of neuropathological assessment of brain amyloidosis (Alafuzoff et al., 2009). However due to epitope specificity 4G8 can cross-react with APP. The presence of A β in neurons is currently highly discussed. It can be clearly evidenced in neuronal cell cultures (Lee et al., 2003) and also in a few AD transgenic mouse lines with very aggressive neuropathology, such as the APPxPS1-Ki and 5xFAD models (Faure et al., 2011; Oakley et al., 2006). However, the presence of A β in neurons of AD murine transgenic is currently highly discussed (Winton et al., 2011; Wirths et al., 2012; Cuello et al., 2012).

Results from our double labelling control experiments revealed that, in mouse lemurs, 4G8-positive intracellular objects do not strictly correspond to APP accumulation. It can be concluded that 4G8 objects in mouse lemurs are mainly composed of A β and not of APP. Intracellular A β deposition is often considered as an early stage of the evolution towards AD either in experimental models (Casas et al., 2004; Walsh et al., 2000) or in humans (Gouras et al., 2000). Interestingly, intracellular A β vanishes as extracellular A β deposition increases (Wirths et al., 2001). This suggests that it is released in the extracellular space before to

aggregate in extracellular A β deposits. Also, there is a balance between the soluble extracellular A β in the brain and in the plasma (Craft et al., 2002). Our data may support a three-phases model of amyloidosis development: (1) First, a low plasmatic amyloid load can be associated either to a low amyloid synthesis which may be the case in young animals and in some aged animals, or to the sequestration of A β in the intra-neuronal space, as seen in the old animals included in our study. (2) Then, A β is released in the extracellular space from where it is exported to the periphery increasing plasma concentration. This would explain the high plasma A β levels found in animals with a low intracellular amyloid load. (3) Data from the literature suggest that later the extracellular A β may also aggregate into parenchymal A β plaques leading to a reduced plasma A β (Song et al., 2011). The phases 1 and 2 of this process match with our observations in lemurs and could explain some findings reported in humans (Song et al., 2011) and dogs (Gonzalez-Martinez et al., 2011) underlining an increased plasmatic A β in early phases of AD or of AD-like age-related pathologies. These events could correspond to a time frame during which amyloid can be released from cells but is not yet aggregated into plaques, hence favouring its passage to the plasmatic compartment.

Other factors could however explain plasmatic A β modulation in our animals. In humans, it was proposed that plasmatic A β pool does not only result from intracerebral A β clearance, but also from peripheral sources such as the skeletal muscle, platelets, and vascular walls, which produce appreciable amounts of A β (Kuo et al., 2000). Also, some plasma proteins such as immunoglobulins, apolipoproteins and proteins of the complement can bind and mask A β peptides or can modulate their metabolism (Roher et al., 2009). Pathological states such as atherosclerotic vascular diseases can also modulate the bioavailability of peripheral A β which appears to bind fatty streaks in atherosclerotic vessels (Roher et al., 2009). We cannot rule out a role of these factors in the regulation of plasma A β in lemurs. Finally, plasmatic A β in lemurs could also be regulated by internal factors such as corticoid levels. Indeed, a study in macaques has shown that plasmatic A β is reduced by chronic exposure to corticoids (Kulstad et al., 2005).

Environmental factors leading to stress and increased glucocorticoid levels might thus also modulate plasmatic A β in lemurs. Longitudinal studies will thus have to be performed to further elucidate the origin of plasmatic A β pool and to study the reason of heterogeneous plasmatic A β in old lemurs. However, our results suggest that in aged animals plasmatic A β can be used as a stratification biomarker to include homogeneous animals in experimental groups for preclinical drug trials that aim at modifying amyloid load.

ACKNOWLEDGEMENTS

This study was financially supported by the France-Alzheimer Association, the National Foundation for Alzheimer's Disease and Related Disorders, and the National Institute on Aging (R01-AG020197). We thank Marion Chaigneau, Diane Houitte and Martine Guillermier for technical assistance.

Disclosure Statement

The authors declare no conflicts of interest.

REFERENCES

- Aho, L., Pikkarainen, M., Hiltunen, M., Leinonen, V., Alafuzoff, I., 2010. Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain, *J. Alzh. Dis.* 20, 1015-1028.
- Alafuzoff, I., Pikkarainen, M., Arzberger, T., Thal, D.R., Al-Sarraj, S., Bell, J., Bodi, I., Budka, H., Capetillo-Zarate, E., Ferrer, I., Gelpi, E., Gentleman, S., Giaccone, G., Kavantzias, N., King, A., Korkolopoulou, P., Kovacs, G.G., Meyronet, D., Monoranu, C., Parchi, P., Patsouris, E., Roggendorf, W., Stadelmann, C., Streichenberger, N., Tagliavini, F., Kretschmar, H., 2008. Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium, *Acta Neuropathol.* 115, 533-546.
- Alafuzoff, I., Thal, D.R., Arzberger, T., Bogdanovic, N., Al-Sarraj, S., Bodi, I., Boluda, S., Bugiani, O., Duyckaerts, C., Gelpi, E., Gentleman, S., Giaccone, G., Graeber, M., Hortobagyi, T., Hoftberger, R., Ince, P., Ironside, J.W., Kavantzias, N., King, A., Korkolopoulou, P., Kovacs, G.G., Meyronet, D., Monoranu, C., Nilsson, T., Parchi, P., Patsouris, E., Pikkarainen, M., Revesz, T., Rozemuller, A., Seilhean, D., Schulz-Schaeffer, W., Streichenberger, N., Wharton, S.B., Kretschmar, H., 2009. Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium, *Acta Neuropathol.* 117, 309-320.
- Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., Blennow, K., 1999. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease, *Arch. Neurol.* 56, 673-680.

- Blennow, K., Hampel, H., Weiner, M., Zetterberg, H., 2010. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease, *Nat. Rev. Neurol.* 6, 131-144.
- Bolte, S., Cordelieres, F.P., 2006. A guided tour into subcellular colocalization analysis in light microscopy, *J. Microscopy* 224, 213-232.
- Bons, N., Mestre, N., Petter, A., 1991. Senile plaques and neurofibrillary changes in the brain of an aged lemurian primate, *Microcebus murinus*, *Neurobiol. Aging* 13, 99-105.
- Bons, N., Sihol, S., Barbier, V., Mestre-Frances, N., Albe-Fessard, D., 1998. A stereotaxic atlas of the grey lesser mouse lemur brain (*Microcebus murinus*), *Brain Res. Bull.* 46, 1-173.
- Buerger, K., Frisoni, G., Uspenskaya, O., Ewers, M., Zetterberg, H., Geroldi, C., Binetti, G., Johannsen, P., Rossini, P.M., Wahlund, L.O., Vellas, B., Blennow, K., Hampel, H., 2009. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI), *Exp. Gerontol.* 44, 579-585.
- Casas, C., Sergeant, N., Itier, J.M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdoux, V., van de Steeg, E., Ret, G., Canton, T., Drobecq, H., Clark, A., Bonici, B., Delacourte, A., Benavides, J., Schmitz, C., Tremp, G., Bayer, T.A., Benoit, P., Pradier, L., 2004. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model, *Am. J. Pathol.* 165, 1289-1300.
- Chang, W.P., Koelsch, G., Wong, S., Downs, D., Da, H., Weerasena, V., Gordon, B., Devasamudram, T., Bilcer, G., Ghosh, A.K., Tang, J., 2004. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors, *J. Neurochem.* 89, 1409-1416.
- Cuello, A.C., Allard, S., Ferretti, M.T., 2012. Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models, *Life Sci.* 91(23-24), 1141-1147.

- Craft, D.L., Wein, L.M., Selkoe, D.J., 2002. A mathematical model of the impact of novel treatments on the A beta burden in the Alzheimer's brain, CSF and plasma, *Bull. Math. Biol.* 64, 1011-1031.
- Das, R., Nachbar, R.B., Edelstein-Keshet, L., Saltzman, J.S., Wiener, M.C., Bagchi, A., Bailey, J., Coombs, D., Simon, A.J., Hargreaves, R.J., Cook, J.J., 2011. Modeling effect of a gamma-secretase inhibitor on amyloid-beta dynamics reveals significant role of an amyloid clearance mechanism, *Bull. Math. Biol.* 73, 230-247.
- Delatour, B., Mercken, L., El Hachimi, K.H., Colle, M.A., Pradier, L., Duyckaerts, C., 2001. FE65 in Alzheimer's disease: neuronal distribution and association with neurofibrillary tangles, *Am. J. Pathol.* 158, 1585-1591.
- Devanand, D.P., Schupf, N., Stern, Y., Parsey, R., Pelton, G.H., Mehta, P., Mayeux, R., 2011. Plasma A beta and PET PiB binding are inversely related in mild cognitive impairment, *Neurology* 77, 125-131.
- Duyckaerts, C., Potier, M.C., Delatour, B., 2008. Alzheimer disease models and human neuropathology: similarities and differences, *Acta Neuropathol.* 115, 5-38.
- Faure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., Dhenain, M., Rampon, C., Delatour, B., 2011. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease, *Neurobiol. Aging* 32, 407-418.
- Fleisher, A.S., Raman, R., Siemers, E.R., Becerra, L., Clark, C.M., Dean, R.A., Farlow, M.R., Galvin, J.E., Peskind, E.R., Quinn, J.F., Sherzai, A., Sowell, B.B., Aisen, P.S., Thal, L.J., 2008. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease, *Arch. Neurol.* 65(8), 1031-1038.

- Garcia-Alloza, M., Robbins, E.M., Zhang-Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., Prada, C., Greenberg, S.M., Bacskai, B.J., Frosch, M.P., 2006. Characterization of amyloid deposition in the APP^{swe}/PS1^{dE9} mouse model of Alzheimer disease, *Neurobiol. Dis.* 24, 516-524.
- Gonzalez-Martinez, A., Rosado, B., Pesini, P., Suarez, M.L., Santamarina, G., Garcia-Belenguer, S., Villegas, A., Monleon, I., Sarasa, M., 2011. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease, *Exp. Gerontol.* 46, 590-596.
- Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard, P., Relkin, N.R., 2000. Intraneuronal A β 42 accumulation in human brain, *Am. J. Pathol.* 156, 15-20.
- Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., Troncoso, J.C., 2001. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome, *Arch. Pathol. Lab. Med.* 125, 489-492.
- Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, *Science* 297, 353-356.
- Jack, C.R., Jr., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Weiner, M., Petersen, R.C., 2009. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease, *Brain* 132, 1355-1365.
- Joseph-Mathurin, N., Dorieux, O., Trouche, S., Boutajangout, A., Kraska, A., Fontès, P., Verdier, J.-M., Sigurdsson, E.M., Mestre-Francés, N., Dhenain, M., 2013. A β immunization in old mouse lemur primates induces cerebral microhemorrhages and accelerates age-associated iron deposits in the choroid plexus, *Neurobiol. Aging* 34, 2613-2622.

- Kawarabayashi, T., Younkin, L.H., Saido, T.C., Shoji, M., Ashe, K.H., Younkin, S.G., 2001. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease, *J. Neurosci.* 21, 372-381.
- Kounnas, M.Z., Danks, A.M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., Yu, C., Pleynt, D., Digregorio, P.J., Velicelebi, G., Stauderman, K.A., Comer, W.T., Mobley, W.C., Li, Y.M., Sisodia, S.S., Tanzi, R.E., Wagner, S.L., 2010. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease, *Neuron* 67, 769-780.
- Kraska, A., Dorieux, O., Picq, J.-L., Petit, F., Bourrin, E., Chenu, E., Volk, A., Perret, M., Hantraye, P., Mestre-Frances, N., Aujard, F., Dhenain, M., 2011. Age associated cerebral atrophy in mouse lemur Primates, *Neurobiol. Aging* 32, 894–906.
- Kulstad, J.J., McMillan, P.J., Leverenz, J.B., Cook, D.G., Green, P.S., Peskind, E.R., Wilkinson, C.W., Farris, W., Mehta, P.D., Craft, S., 2005. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque, *J. Neuropathol. Exp. Neurol.* 64, 139-146.
- Kuo, Y.M., Kokjohn, T.A., Watson, M.D., Woods, A.S., Cotter, R.J., Sue, L.I., Kalback, W.M., Emmerling, M.R., Beach, T.G., Roher, A.E., 2000. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism, *Am. J. Pathol.* 156, 797-805.
- Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L., 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers, *J. Neurosci.* 24, 10191-10200.
- Lanz, T.A., Wood, K.M., Richter, K.E., Nolan, C.E., Becker, S.L., Pozdnyakov, N., Martin, B.A., Du, P., Oborski, C.E., Wood, D.E., Brown, T.M., Finley, J.E., Sokolowski, S.A., Hicks,

- C.D., Coffman, K.J., Geoghegan, K.F., Brodney, M.A., Liston, D., Tate, B., 2010. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014, *J. Pharmacol. Exp. Ther.* 334, 269-277.
- Lee, E.B., Skovronsky, D.M., Abtahian, F., Doms, R.W., Lee, V.M., 2003. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons, *J. Biol. Chem.* 278, 4458-4466.
- Lemere, C.A., 2009. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine, *Prog. Brain. Res.* 175, 83-93.
- Lemere, C.A., Beierschmitt, A., Iglesias, M., Spooner, E.T., Bloom, J.K., Leverone, J.F., Zheng, J.B., Seabrook, T.J., Louard, D., Li, D., Selkoe, D.J., Palmour, R.M., Ervin, F.R., 2004. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet, *Am. J. Pathol.* 165, 283-297.
- Liu, L., Duff, K., 2008. A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse, *Journal of Visualized Experiments* (DOI: 10.3791/960), <http://www.jove.com/index/Details.stp?ID=960>.
- Lopez, O.L., Kuller, L.H., Mehta, P.D., Becker, J.T., Gach, H.M., Sweet, R.A., Chang, Y.F., Tracy, R., DeKosky, S.T., 2008. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study, *Neurology* 70, 1664-1671.
- Mestre-Frances, N., Keller, E., Calenda, A., Barelli, H., Checler, F., Bons, N., 2000. Immunohistochemical analysis of cerebral cortical and vascular lesions in the primate *Microcebus murinus* reveal distinct amyloid beta 1-42 and beta 1-40 immunoreactivity profiles, *Neurobiol. Dis.* 7, 1-8.
- Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al., 1995. Reduction of beta-amyloid

peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease, *Ann. Neurol.* 38, 643-648.

Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation, *J. Neurosci.* 26, 10129-10140.

Picq, J.L., Aujard, F., Volk, A., Dhenain, M., 2012. Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments, *Neurobiol. Aging* 33, 1096–1109.

Relkin, N.R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R.W., Younkin, S., Younkin, L., Schiff, R., Weksler, M.E., 2009. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, *Neurobiol. Aging* 30, 1728-1736.

Roher, A.E., Esh, C.L., Kokjohn, T.A., Castano, E.M., Van Vickle, G.D., Kalback, W.M., Patton, R.L., Luehrs, D.C., Dausgs, I.D., Kuo, Y.M., Emmerling, M.R., Soares, H., Quinn, J.F., Kaye, J., Connor, D.J., Silverberg, N.B., Adler, C.H., Seward, J.D., Beach, T.G., Sabbagh, M.N., 2009. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease, *Alzheimers Dement.* 5, 18-29.

Sauvee, M., DidierLaurent, G., Latache, C., Escanye, M.C., Olivier, J.L., Malaplate-Armand, C., 2014. Additional use of aβ₄₂/aβ₄₀ ratio with cerebrospinal fluid biomarkers p-tau and aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice, *J. Alzheimers Dis.* 41(2), 377-386.

Selkoe, D.J., 2008. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior, *Behav. Brain Res.* 192, 106-113.

- Sharman, M.J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I.J., Lim, W.L., Singh, S., Wenk, M.R., Ghiso, J., Buxbaum, J.D., Gandy, S., Martins, R.N., 2010. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice, *J. Alzheimers Dis.* 21, 403-409.
- Slaets, S., Le Bastard, N., Martin, J.J., Slegers, K., Van Broeckhoven, C., De Deyn, P.P., Engelborghs, S., 2013. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels, *J. Alzheimers Dis.* 36(4), 759-767.
- Sobow, T., Flirski, M., Kloszewska, I., Liberski, P.P., 2005. Plasma levels of alpha beta peptides are altered in amnesic mild cognitive impairment but not in sporadic Alzheimer's disease, *Acta Neurobiol. Exp.* 65, 117-124.
- Song, F., Poljak, A., Valenzuela, M., Mayeux, R., Smythe, G.A., Sachdev, P.S., 2011. Meta-Analysis of Plasma Amyloid-beta levels in Alzheimer's Disease, *J. Alzh. Dis.* 25, 1-11.
- Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R., Kaye, J., Montine, T.J., Park, D.C., Reiman, E.M., Rowe, C.C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M.C., Thies, B., Morrison-Bogorad, M., Wagster, M.V., Phelps, C.H., 2011. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup, *Alzheimer's and Dementia* 7, 280-292.
- Strozyk, D., Blennow, K., White, L.R., Launer, L.J., 2003. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study, *Neurology* 60, 652-656.
- Trouche, S.G., Asuni, A., Boutajangout, A., Frangione, B., Wisniewski, T., Rouland, S., Verdier, J.M., Sigurdsson, E.M., Mestre-Frances, N., 2008. Neuropathological evaluation of the

- nonhuman primate *Microcebus murinus* immunized with K6Abeta1-30, an Abeta derivative, *Alzheimers Dement.* 4(4-Suppl2), T211.
- Trouche, S.G., Asuni, A., Rouland, S., Wisniewski, T., Frangione, B., Verdier, J.M., Sigurdsson, E.M., Mestre-Frances, N., 2009. Antibody response and plasma Abeta1-40 levels in young *Microcebus murinus* primates immunized with Abeta1-42 and its derivatives, *Vaccine* 27, 957-964.
- Walsh, D.M., Tseng, B.P., Rydel, R.E., Podlisny, M.B., Selkoe, D.J., 2000. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain, *Biochem.* 39, 10831-10839.
- Wang, A., Das, P., Switzer, R.C., 3rd, Golde, T.E., Jankowsky, J.L., 2011. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy, *J. Neurosci.* 31, 4124-4136.
- West, M.J., Slomianka, L., Gundersen, H.J.G., 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator, *Anatomic. Rec.* 231, 482-497.
- Wiltfang, J., Esselmann, H., Bibl, M., Hull, M., Hampel, H., Kessler, H., Frolich, L., Schroder, J., Peters, O., Jessen, F., Luckhaus, C., Perneczky, R., Jahn, H., Fiszer, M., Maler, J.M., Zimmermann, R., Bruckmoser, R., Kornhuber, J., Lewczuk, P., 2007. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load, *J. Neurochem.* 101(4), 1053-1059.
- Winton, M.J., Lee, E.B., Sun, E., Wong, M.M., Leight, S., Zhang, B., Trojanowski, J.Q., Lee, V.M., 2011. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration, *J. Neurosci.* 31, 7691-7699.

- Wirhth, O., Dins, A., Bayer, T.A., 2012. AbetaPP accumulation and/or intraneuronal amyloid-beta accumulation? The 3xTg-AD mouse model revisited, *J. Alzheimers Dis.* 28(4), 897-904.
- Wirhth, O., Multhaup, G., Bayer, T.A., 2004. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade, *J. Neurochem.* 91, 513-520.
- Wirhth, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., Bayer, T.A., 2001. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice, *Neurosci. Lett.* 306, 116-120.
- Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., Iwatsubo, T., 2009. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta, *J. Neurosci.* 29, 11393-11398.

FIGURE LEGENDS

Figure 1.

A. Plasma A β_{40} in mouse lemurs primates (n=25 young animals (1-5.5 years) and n=33 aged animals (5.5-10 years)). A β levels were classified either as low (≤ 55 pg/ml; dark or green spots) or high levels (>55 pg/ml; white or red spots). A larger number of animals older than 5.5 years had a high A β level as compared to young animals. The green and red spots correspond to animals that were studied by histology. The yellow ring corresponds to an animal that had extracellular amyloid deposits. B. Number of neurons presenting intracellular A β positive profiles in the caudate, parietal cortex and hippocampus of animals with low and high plasmatic A β loads (data represent mean \pm SEM). C. Plot fitting plasmatic A β and the density of intracellular A β aggregates in the caudate of aged animals. The values on the side of the dots are ages of the animals at blood sampling. The curve represents a logarithmic fit between intracellular A β and plasmatic A β . A significant negative correlation was found between intracellular A β and plasmatic A β ($r=-0.86$, $p<0.05$).

Figure 2.

A β deposits in brain tissues of aged mouse lemurs (4G8 staining). A-F. Comparison of A β deposits in animals with low (A, C, E) and high (B, D, F) plasmatic amyloid load. A-B. Low resolution image showing the caudate (cd), corpus callosum (cc) and internal capsula (ci). C-F. Higher magnification images showing intracellular amyloid deposits (arrows) in the caudate. G. High magnification image processed with the 3D mode algorithm of exploranova software showing various types of intracellular deposits: spherical vesicles with a low density (1); spherical vesicles with an increased density providing an aspect of diffuse deposition (2); densely packed vesicles (3). H. Extracellular amyloid plaques as seen in the cortex of only one animal. Scale bars: A-B, H: 200 μ m, C-G: 50 μ m.

Figure 3.

Identification of the nature of the 4G8-positive intracellular deposits. A-B. Immunofluorescent stained sections showing the location of 4G8 (red) and A8717-positive (green) objects. A. Example showing cells labeled only with 4G8 or with A8717. B. Example showing different locations of 4G8 and A8717-positive objects within the same neuron. C. The overlap coefficients were low between objects detected by the 4G8 or the A8717 antibodies (C). Scale Bars = 10 μm .

Figure 1.




Figure 2.




Figure 3

